JNJ Jan 2021 180.000 put

OPR - OPR Delayed price. Currency in USD
36.10
0.00 (0.00%)
As of 10:25AM EST. Market open.
Stock chart is not supported by your current browser
Previous close36.10
Open36.10
Bid32.75
Ask34.80
Strike180.00
Expiry date2021-01-15
Day's range36.10 - 36.10
Contract rangeN/A
Volume21
Open interest105
  • Bloomberg

    J&J Looks to Fend Off Challenges to Key Drugs, Consumer Products

    (Bloomberg) -- Johnson & Johnson posted weaker-than-expected sales in the final quarter of 2019, raising the stakes for the health-care conglomerate as it banks on new cancer and immunology drugs to replace a group of aging blockbusters.Some of the company’s most lucrative medicines are facing competition from generics and biosimilars. Arthritis drug Remicade’s sales fell more than 16% from a year earlier in the quarter, while Zytiga, an older treatment for prostate cancer, saw a nearly 14% decline.At the same time, J&J’s storied consumer businesses are also being pressed by upstarts. Sales of its baby-care products declined more than 26% in the U.S. as consumers increasingly look for alternatives to the company’s shampoos, lotions and other one-time medicine-cabinet staples.As the company adapts to those changes, it also is confronting increasing political blowback over high drug prices, trade turbulence and a series of lawsuits tied to a range of its products, from opioids to baby powder.“We face a variety of challenges from debates about the health-care system in our country to uncertainty with global trade to today’s litigious environment, to name a few,” said Chief Executive Officer Alex Gorsky on a conference call with investors Wednesday.Overall, the New Brunswick, New Jersey-based company reported fourth-quarter revenue of $20.75 billion, just short of the $20.87 billion analysts had expected.J&J shares declined 0.9% to $147.93 at 10:47 a.m. in New York on Wednesday. They had advanced 16% in the past 12 months through Tuesday’s close.Income DriverIn the year ahead, J&J is likely to draw much of its growth from sales of cancer and immunology drugs. For 2020, adjusted earnings per share are expected to be $8.95 to $9.10. Heading into Wednesday’s results, Wall Street analysts had expected $9.09, on average.Indeed, such drugs were already a bright spot in the fourth quarter. Sales of Stelara, a treatment for psoriasis, jumped 18% to $1.7 billion. Cancer drug Darzalex brought in $830 million in the quarter, up 42% from a year ago.“Darzalex is transforming the field of multiple myeloma right now,” Jan G. J. van de Winkel, the CEO of Danish biotech Genmab, which collaborated with J&J’s Janssen unit to develop Darzalex, said in an interview last week. “It’s a substantial income driver that any company would be happy about.”Chief Financial Officer Joseph Wolk said J&J is focused on highlighting such best-in-class assets, while potentially shedding those that are growing more slowly.“We continually look and manage our portfolio in a very rigorous fashion, making sure that we are the best owners of the assets that we have on that,” he said on Wednesday. “That works both ways. So we look to complement our portfolio, but we’ll also look to take underperforming businesses and create value for shareholders in other ways.”Other HeadwindsGorsky told investors on Wednesday he was “extremely proud overall with the performance of our pharmaceutical group,” but was particularly impressed with the immunology vertical’s ability to mitigate biosimilar impact on Remicade.“Despite the mixed results” this quarter, Cantor Fitzgerald analyst Louise Chen said she would continue to recommend J&J “as one of our top ideas in 2020.” Chen has an overweight rating on the stock.Concerns about the company’s legal exposure have cast a shadow over its shares at times. J&J has been fighting more than 100,000 suits alleging injuries and illnesses caused by its baby powder, opioid painkillers and other products, though it’s scored a few wins in the courtroom of late.The company had about $5.1 billion in litigation expenses in 2019, it said Wednesday, including a $4 billion charge associated with a proposed deal to resolve all claims accusing the company of helping fuel the U.S. opioid epidemic. A final agreement has yet to be reached.\--With assistance from Jef Feeley.To contact the reporter on this story: Riley Griffin in New York at rgriffin42@bloomberg.netTo contact the editors responsible for this story: Drew Armstrong at darmstrong17@bloomberg.net, Timothy Annett, Mark SchoifetFor more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.

  • J&J forecasts weak annual profit, misses revenue estimates
    Reuters

    J&J forecasts weak annual profit, misses revenue estimates

    Shares of the healthcare conglomerate fell nearly 2% to $146.62 after it reported a rare miss on quarterly revenue, as sales of cancer drug Imbruvica and psoriasis treatment Stelara came in below lofty Wall Street estimates. J&J's pharmaceuticals unit, which makes up half of the company's overall sales, has powered much of its recent growth.

  • Breaking Q4 Earnings News
    Zacks

    Breaking Q4 Earnings News

    Breaking Q4 Earnings News

  • J&J's (JNJ) Q4 Earnings Surpass Estimates, Sales Fall Short
    Zacks

    J&J's (JNJ) Q4 Earnings Surpass Estimates, Sales Fall Short

    J&J (JNJ) comes up with mixed fourth-quarter 2019 results.

  • Chicago Econ Numbers & More Q4 Earnings: JNJ, ABT, FITB
    Zacks

    Chicago Econ Numbers & More Q4 Earnings: JNJ, ABT, FITB

    Certain weeks of the year are rife with important information for the stock market. This is not one of those weeks.

  • Johnson & Johnson (JNJ) Q4 Earnings Beat Estimates
    Zacks

    Johnson & Johnson (JNJ) Q4 Earnings Beat Estimates

    Johnson & Johnson (JNJ) delivered earnings and revenue surprises of 1.08% and -0.21%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

  • J&J Raises Underlying Guidance After Strong Q4, but Legal Risks Linger
    Investing.com

    J&J Raises Underlying Guidance After Strong Q4, but Legal Risks Linger

    Johnson & Johnson (NYSE:JNJ) raised its guidance for underlying earnings and revenue after a strong fourth quarter on Wednesday but was unable to stop reported earnings slumping due to costs related to opioid- and talc-related lawsuits. The company announced fourth-quarter adjusted earnings of $1.88 a share for the quarter, 1c ahead of forecasts, but reported earnings tumbled by 54% to only 66c. Revenue also fell short of forecasts slightly at $20.75 billion.

  • Rally Pauses as Coronavirus Spreads to U.S.
    Zacks

    Rally Pauses as Coronavirus Spreads to U.S.

    Rally Pauses as Coronavirus Spreads to U.S.

  • Why Earnings Season Could Be Great for Johnson & Johnson (JNJ)
    Zacks

    Why Earnings Season Could Be Great for Johnson & Johnson (JNJ)

    Johnson & Johnson (JNJ) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

  • Reuters - UK Focus

    Pharma firms not making enough progress against superbugs - report

    Drug companies are not making progress against the spread of antibiotic resistance at a scale and speed great enough to tackle the global health threat posed by superbugs, a key benchmark analysis found on Tuesday. The findings of a second Antimicrobial Resistance (AMR) Benchmark report showed that while a few pharmaceutical companies are expanding their efforts, change is not happening at the scale needed to radically impact the problem. In India, drug resistance exceeds 70% for many widespread bacteria, the AMR report said.

  • Fourth Quarter Earnings Reports in Week Ahead
    Zacks

    Fourth Quarter Earnings Reports in Week Ahead

    Fourth Quarter Earnings Reports in Week Ahead

  • On MLK Day, a Busy Week Expected
    Zacks

    On MLK Day, a Busy Week Expected

    Q4 earnings season, the World Economic Forum in Davos and President Trump's impeachment trial all get underway beginning tomorrow.

  • Netflix, Johnson & Johnson, Procter & Gamble and Intel are part of Zacks Earnings Preview
    Zacks

    Netflix, Johnson & Johnson, Procter & Gamble and Intel are part of Zacks Earnings Preview

    Netflix, Johnson & Johnson, Procter & Gamble and Intel are part of Zacks Earnings Preview

  • AstraZeneca Announces Positive FDA Updates on Cancer Drugs
    Zacks

    AstraZeneca Announces Positive FDA Updates on Cancer Drugs

    AstraZeneca's (AZN) label expansion application for Lynparza in a prostate cancer indication gets priority review from the FDA. Imfinzi and pipeline candidate, tremelimumab get orphan drug status for liver cancer.

  • J&J's $8B Jury Award in Risperdal Case Cut to $6.8M by Judge
    Zacks

    J&J's $8B Jury Award in Risperdal Case Cut to $6.8M by Judge

    A Philadelphia judge slashes J&J's (JNJ) punitive damages in a lawsuit, which claims that the company did not warm men that they could grow breasts by using its antipsychotic drug, Risperdal.

  • Earnings, Davos — What to know in the week ahead
    Yahoo Finance

    Earnings, Davos — What to know in the week ahead

    It is a shortened trading week and investors will be focused on earnings and the World Economic Forum taking place in Davos, Switzerland.

  • If You Had Bought Johnson & Johnson (NYSE:JNJ) Shares Five Years Ago You'd Have Made 46%
    Simply Wall St.

    If You Had Bought Johnson & Johnson (NYSE:JNJ) Shares Five Years Ago You'd Have Made 46%

    If you buy and hold a stock for many years, you'd hope to be making a profit. Better yet, you'd like to see the share...

  • Q4 Earnings Season Showing Revenue Momentum
    Zacks

    Q4 Earnings Season Showing Revenue Momentum

    Q4 Earnings Season Showing Revenue Momentum

  • The Zacks Analyst Blog Highlights: AAPL, JNJ, PG and AXP
    Zacks

    The Zacks Analyst Blog Highlights: AAPL, JNJ, PG and AXP

    The Zacks Analyst Blog Highlights: AAPL, JNJ, PG and AXP

  • The Zacks Analyst Blog Highlights: JPM, JNJ, CVX and PG
    Zacks

    The Zacks Analyst Blog Highlights: JPM, JNJ, CVX and PG

    The Zacks Analyst Blog Highlights: JPM, JNJ, CVX and PG

  • The Zacks Analyst Blog Highlights: JNJ, BHP, MCO, NVDA and DAL
    Zacks

    The Zacks Analyst Blog Highlights: JNJ, BHP, MCO, NVDA and DAL

    The Zacks Analyst Blog Highlights: JNJ, BHP, MCO, NVDA and DAL

By using Yahoo, you agree that we and our partners can use cookies for purposes such as customising content and advertising. See our Privacy Policy to learn more